West syndrome is classified as an epileptic encephalopathy. This syndrome is diagnosed in children aged 4-6 months. Its unsuccessful prognosis and complicated aetiology affects the delay of psychomotor development and cognitive functions of children. Repeated attacks inhibit the realization of next tasks assigned to the children’s age. Properly conducted treatment of West syndrome should be interdisciplinary and include pharmacological treatment, diet and rehabilitation. Pharmacological treatment of West syndrome includes: the ACTH hormone, corticosteroids (prednisolone), vigabatrin, valproic acid, nitrazepam, pyridoxine, zonisamide, topiramide. The therapy includes also a ketogenic diet which assumes changes in the proportion of nutrients. Predominant ingredient in the diet are fats (80-90% of daily intake of nutrients). Further, children with West syndrome require neuropsychological and motor rehabilitation (Vojta therapy, NDT- Bobath therapy).
Cooperation of therapeutic experts with parents of the children makes it possible to achieve therapeutic benefits through improvement of the children's quality of life. Mental disability and cognitive impairment associated with the syndrome result in the loss of skills already acquired by children, therefore motivation and support of the children's parents is a significant task assigned to therapeutic team members.

West syndrome, children, therapy, treatment

Rudzka-Dybała, M. (2015). Wzorce zapisu EEG u dzieci z zespołem Westa. [EEG record patterns in children with West syndrome]. Przegląd Lekarski, 72(11), 694-696.

Mojs, E., Gajewska, E. (2007). Problemy diagnostyczne i terapeutyczne dzieci z zespołem Westa. [Diagnostic and therapeutic problems of children with West syndrome]. Roczniki Pomorskiej Akademii Medycznej, 53(1),68-71.

Szczepanik, E., Mazurczak, T., Hoffman-Zacharska, D., Nawara, M. (2007). Zespół Westa sprzężony z chromosomem X. [West syndrome coniugated with the X chromosome]. Neurologia Dziecięca,16(31),29-33.

Ault, K.A., Future II Study Group. (2007). Effect of prophylactic human papillomavirus L1 virus−like−particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet, 369, 1861-1868.

Lagaea, L., Verhelst, H., Ceulemansc, B., de Meirleird, L., Nassogne, M.C.,de Borchgravef, V., Foulon, M., van Bogaerti, P. (2010).Treatment and long term outcome in West syndrome: The clinical reality. A multicenter follow up study. Seizure, 19(3),159-164.

Mackay, M.T., Weiss, S.K., Adams-Webber, T., Ashwal, S., Stephens, D., Ballaban-Gill, K., Baram, T.D., Duchowny, M., Hirtz, D., Pellock, J.M., Shields, W.D., Shinnar, S., Wyllie, E., Snead, O.C. (2004). Praktyczne wytyczne dotyczące farmakologicznego leczenia napadów zgięciowych Raport American Academy of Neurology and Child Neurology Society. [Practical guidelines on the pharmacological treatment of flexion attacks Raport American Academy of Neurology and Child Neurology Society]. Neurology, 62,1668-1681.

Wheless, J.W., Gibson, P., Luther Rosbeck, K., Hardin, M., O’Dell, Ch., Whittemore, V., Pellock, J.M. (2012). Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. BMC Pediatrics,12,108.

Lux, A.L., Osbone, J.P. (2004). A proposal for care definitions and outcome measures in studies of infantile spasm and west syndrome: consensus statement of the west Delphi group. Epilepsia, 45(11),1416-1428.

Nelson, G.R. (2015). Management of infantile spasms. Translational Pediatrics, 4(4),260-270.

Gajewska, E., Mojs, E., Sobieska, M., Samborski, W. (2005). Development and psychokinetic therapy of children suffering from West Syndrome – an overview. Roczniki Akademii Medycznej w Białymstoku, 50,297-301.

Grzegorczyk, A., Szewczyk, L. (2016). Ocena wsparcia społecznego rodziców dzieci z chorobami neurologicznymi. [Evaluation of social support for parents of children with neurological diseases]. Aspekty zdrowia i choroby, 1(4),55-64.

Dytrych, G. (2008). Kontrowersje wokół metody Vojty – spojrzenie terapeuty. [Controversy related to the Vojta method - therapist's opinion]. Neurologia Dziecięca, 17 (33), 59-62.

Bagnowska, K., Falkowski, M. (2013). Wybrane metody usprawniania dzieci z mózgowym porażeniem dziecięcym. [Selected methods of improving children with cerebral palsy]. Nowa Pediatria, 3,119-123.

Mikołajewka, E., Mikołajewski, D. (2016). Metoda Bobath w rehabilitacji dorosłych i dzieci. [The Bobath method in the rehabilitation of adults and children].Niepełnosprawność- zagadnienia, problemy, rozwiązania, 1(18),7-24.

Chochowska, M., Zgorzalewicz-Stachowiak, M., Sereda-Wiszowaty, E. (2008). Wpływ wybranych czynników na skuteczność metody NDT- Bobath w usprawnianiu dzieci z mózgowym porażeniem dziecięcym. [The influence of selected factors on the effectiveness of the NDT-Bobath method in improving children with cerebral palsy]. Fizjoterapia, 16 (3), 8-24.

Chorygiewicz, T., Arnowska, I., Gysior, M. (2010). Przeciwdrgawkowe i neuroprotekcyjne działanie diety ketogennej. [Anticonvulsive and neuroprotective effect of the ketogenic diet]. Przegląd Lekarski, 67(3),205-212.

Azevedo de Lima, P., Pereira, de Brito Sampaio, L., Raquel, N., Damasceno, T. (2014). Neurobiochemical mechanism of a ketogenic diet in refractory epilepsy. Clinics, 69(10),699-705.

Kossoff, E.H., Pyzik, P.L., McGrogan, J.R., Vining, E.P., Freeman, J.M. (2002). Efficacy of the ketogenic diet for infantile spasms. Pediatrics, 109 (5), 780-783.

Hong, A.M., Turner, Z., Hamdy, R.F., Kossoff, E.H. (2010). Infantile spasms treated with ketogenic diet: prospective single-center experience in 104 consecutive infants. Epilepsia,51(8),1403-1407.